Skip to Content
Merck
  • Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities.

Honokiol analogs: a novel class of anticancer agents targeting cell signaling pathways and other bioactivities.

Future medicinal chemistry (2013-05-09)
Ankit Kumar, Umesh Kumar Singh, Anurag Chaudhary
ABSTRACT

Honokiol (3,5-di-(2-propenyl)-1,1-biphenyl-2,2-diol) is a natural bioactive neolignan isolated from the genus Magnolia. In recent studies, honokiol has been observed to have anti-angiogenic, anticancer, anti-inflammatory, neuroprotective and GABA-modulating properties in vitro and in preclinical models. Honokiol and its analogs target multiple signaling pathways including NF-κB, STAT3, EGFR, mTOR and caspase-mediated common pathway, which regulate cancer initiation and progression. Honokiol and its targets of action may be helpful in the development of effective analogs and targeted cancer therapy. In this review, recent data describing the molecular targets of honokiol and its analogs with anticancer and some other bioactivities are discussed.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Honokiol, ≥98% (HPLC), powder
Honokiol, European Pharmacopoeia (EP) Reference Standard
Supelco
Honokiol, analytical standard